Biosimilar costs escalate for GI practices (AGA)

Pharmacy benefit managers (PBMs) influence access to prescription drugs by negotiating rebates from manufacturers in exchange for formulary placement. While insurers benefit from these rebates, they often disadvantage GI practices by restricting access to biosimilars, impacting patient care. The Federal Trade Commission has acknowledged the significant power PBMs hold, and the medical community is advocating for change.